Rare growth disorders can be the result of various genetic mutations, environmental factors such as malnutrition, abnormalities in bone and cartilage development, or secondary to chronic illness.
The signs and symptoms of individuals with growth disorders can vary widely but they all have in common abnormalities in height, weight and sexual maturation. We look at the current and future treatment landscape of these disorders, says Dr Nicola Davies in her exclusive column for The Pharma Letter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze